.svg)
Renue Lifesciences
Pioneering the Future of Cellular Health
"Reprogram.
Regenerate.
Rejuvenate.
Renue"
unlocking the potential of cellular health by repairing damage, reprogramming function, regenerating vitality, rejuvenating tissues, and renewing life through personalized medicine.
The future of precision medicine
Advancements in cell and gene therapies
We Believe -
A future where longevity is optimized, disease is mitigated, and personalized medicine is accessible. By integrating computational biology, gene compensation, Yamanaka factors, cellular therapies, molecular science, and AI-driven technology, we reprogram cells, restore function, and redefine human health.
95%
20Y
Transforming Lives with Breakthrough Therapies
Key Advantages
(01)
Ethical and precise rejuvenation of
cells without converting them into
stem cells.
(02)
Targeting CAR-T cells, engineered NK
cells, genetic disorders, IVF, and blood
transfusions.
(03)
Rejuvenation of neurons, blood, brain
barriers, cosmetics, and skincare.
The Science of Cellular Rejuvenation and Reprogramming
"Reimagining longevity and resilience by developing transformative solutions that reprogram, regenerate, rejuvenate
and renue at the cellular level redefining the possibilities of life"
Reprogramming Health Through Computational Innovation.
“ We are at the tipping point of regenerative medicine—where AI, cellular reprogramming, and gene compensation converge to redefine aging and disease treatment at its core. ”
“Our work at Renue is not just about extending lifespan, but enhancing healthspan—leveraging computation to overcome disease, rejuvenate cells, restore function, and unlock the body's innate potential for renewal.”
Affordable Excellence in Research Services
Dui venenatis dolor metus vel sed vel nam.- Nunc consectetur varius at praesent duis.
- Tortor aliquam et dignissim ultrices. Nibh sed.
- Ac dui sed pretium orci habitant sed cursus.
- Pellentesque convallis purus est nam
- Augue viverra orci venenatis leo nisl feugiat.
- Libero enim senectus blandit donec cursus.
- Et enim tortor ultrices eu turpis dictum iaculis.
- Pretium commodo adipiscing congue egestas.
- Quisque purus porttitor dui risus. Nisi donec.
- Velit elementum lectus suspendisse facilisis.
- Interdum auctor molestie elementum egestas.
- Aliquet mauris neque sit tristique id pretium.
- Vel quis sollicitudin ultricies diam nec ut.
- Ut auctor nullam elementum volutpat.
Frequently asked question
What is Renue’s approach to regenerative medicine?
Renue LifeSciences integrates AI-driven computation, gene compensation, and cellular reprogramming to restore function at the molecular level. Our proprietary frameworks and models leverage Yamanaka factors, mRNA technology, and computational biology to target aging, degenerative diseases, and tissue regeneration with unprecedented precision.
How does Renue see the future of healthcare and longevity?
We envision a future where disease and aging are no longer inevitable. By combining advanced molecular science with AI-driven tools, we are redefining healthcare—shifting from reactive treatment to proactive cellular restoration. Our long-term goal is to create accessible, personalized regenerative solutions that extend healthspan and optimize human vitality.
Why is now the right time for regenerative breakthroughs?
With advances in computational biology, AI modeling, and molecular reprogramming, we are at a pivotal moment in scientific discovery. The convergence of these technologies allows us to accelerate research, validate therapies faster, and develop interventions that were previously impossible. Now is the time to harness this momentum to transform longevity and disease treatment.
What makes Renue different from other regenerative medicine companies?
Renue is pioneering a computational-first approach to regenerative medicine, integrating AI, cellular engineering, and proprietary predictive models to accelerate discovery by 20-30%. Unlike traditional biotech, we focus on precision-driven cellular reprogramming that not only treats symptoms but restores cellular health at its core, driving long-term, scalable impact.
How is the regenerative medicine market expected to grow in the coming years?
The global regenerative medicine market is rapidly expanding, valued at $32.1 billion in 2023 and projected to reach $531.7 billion by 2033, growing at a 32.4% CAGR. This surge is driven by AI-driven cellular reprogramming, gene therapies, tissue engineering, and the rising demand for personalized medicine. As regenerative healthcare advances, Renue leads in developing breakthrough therapies to restore cellular function, combat aging, and redefine longevity.
Why is the aging population a key driver for regenerative medicine?
Starting in 2030, older Americans will make up 21% of the U.S. population, up from 15% today. By 2060, nearly one in four will be 65+, the 85+ population will triple, and centenarians will exceed 500,000. This shift creates an urgent need for longevity-focused healthcare to address age-related diseases, cellular degeneration, and declining immunity. Renue’s AI-driven regenerative therapies aim to extend healthspan, reduce disease burden, and improve quality of life for aging populations.
Publications
Perli, S. D., Cui, C. H., & Lu, T. K. (2016). Continuous genetic recording with self-targeting CRISPR-Cas in human cells. Science, 353(6304). doi:10.1126/science.aag0511 Read more
Takahashi, K., Jeong, D., Wang, S., Narita, M., Jin, X., Iwasaki, M, Perli, Yamanaka, S. (2020). Critical Roles of Translation Initiation and RNA Uridylation in Endogenous Retroviral Expression and Neural Differentiation in Pluripotent Stem Cells. Cell Rep, 31(9), 107715. doi:10.1016/j.celrep.2020.107715 Read more
Nissim, L., Perli, S. D., Fridkin, A., Perez-Pinera, P., & Lu, T. K. (2014). Multiplexed and programmable regulation of gene networks with an integrated RNA and CRISPR/Cas toolkit in human cells. Mol Cell, 54(4), 698-710. doi:10.1016/j.molcel.2014.04.022 Read more
